[Skip to Content]
[Skip to Content Landing]
Views 303
Citations 0
Invited Commentary
May 2017

Determining the Value of Home Monitoring of Patients With Age-Related Macular Degeneration

Author Affiliations
  • 1Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California
  • 2Veterans Affairs Palo Alto Health Care System, Palo Alto, California
  • 3Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor
  • 4Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor
JAMA Ophthalmol. 2017;135(5):459-460. doi:10.1001/jamaophthalmol.2017.0133

With the aging of the US population, the number of persons with age-related macular degeneration (AMD) is expected to rapidly increase in coming decades. Currently, more than 11 million persons are affected by this sight-threatening condition, and the prevalence is expected to double by 2050.1,2 Rates of other common ocular diseases of aging, such as cataract, glaucoma, and diabetic retinopathy, are also expected to rapidly increase. This projection begs the question of how eye care professionals are going to be able to continue to provide high-quality and timely care to all these patients in the years to come.